TRexBio, a clinical-stage biotechnology company, has announced it has secured $50.0 million in new funding. This investment round will support the company's ongoing efforts in discovering and developing immunoregulatory medicines. Headquartered in South San Francisco, California, TRexBio focuses on leveraging tissue Treg biology to address inflammatory diseases.
The company's core approach centers on its Deep Biology platform, which utilizes cutting-edge computational biology tools, a strong focus on human tissue, and deep immunobiology expertise. This platform is designed to map human tissue Treg behavior to specific disease processes, enabling the identification and characterization of novel targets for therapeutic intervention. TRexBio's lead program, TRB-061, is currently undergoing a Phase 1 clinical trial for atopic dermatitis. TRB-061 is a novel TNFR2-selective agonist engineered to activate and expand effector Tregs within tissues, aiming to restore immune balance in various inflammatory conditions.
The newly raised capital is intended to accelerate the advancement of TRexBio's clinical pipeline and further enhance its Deep Biology platform capabilities. This funding round underscores investor confidence in the company's innovative approach to immunoregulatory medicine and its potential to develop transformative treatments for patients suffering from inflammatory diseases. The investment will be crucial in progressing TRB-061 through its clinical development stages and expanding the company's research into additional therapeutic targets.
Looking ahead, TRexBio plans to utilize this significant investment to solidify its position as a leader in tissue Treg biology. The company aims to broaden its understanding of immune regulation and translate these insights into a robust portfolio of medicines, ultimately striving to bring novel therapies to patients with unmet medical needs.
